Your browser doesn't support javascript.
loading
A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.
Ahearn, Aaron J; Thin Maw, Thin; Mehta, Rishi; Emamaullee, Juliet; Kim, Jim; Blodget, Emily; Kahn, Jeffrey; Sher, Linda; Genyk, Yuri.
Affiliation
  • Ahearn AJ; Department of Surgery, Keck Medical Center, University of Southern California, Los Angeles, CA.
  • Thin Maw T; Department of Medicine, Keck Medical Center, University of Southern California, Los Angeles, CA.
  • Mehta R; Department of Medicine, Keck Medical Center, University of Southern California, Los Angeles, CA.
  • Emamaullee J; Department of Surgery, Keck Medical Center, University of Southern California, Los Angeles, CA.
  • Kim J; Department of Surgery, Keck Medical Center, University of Southern California, Los Angeles, CA.
  • Blodget E; Department of Medicine, Keck Medical Center, University of Southern California, Los Angeles, CA.
  • Kahn J; Department of Medicine, Keck Medical Center, University of Southern California, Los Angeles, CA.
  • Sher L; Department of Surgery, Keck Medical Center, University of Southern California, Los Angeles, CA.
  • Genyk Y; Department of Surgery, Keck Medical Center, University of Southern California, Los Angeles, CA.
Transplantation ; 106(2): e153-e157, 2022 02 01.
Article in En | MEDLINE | ID: mdl-34519680

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Neutralizing / Antibodies, Monoclonal, Humanized / Transplant Recipients / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment / Hospitalization Type of study: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Transplantation Year: 2022 Document type: Article Affiliation country: Canada Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Neutralizing / Antibodies, Monoclonal, Humanized / Transplant Recipients / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment / Hospitalization Type of study: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Transplantation Year: 2022 Document type: Article Affiliation country: Canada Country of publication: United States